LXRX - NASDAQ
Lexicon Pharmaceuticals, Inc.
$1.85
-2.1%Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain. The company has strategic collaboration and license agreements with Bristol-Myers Squibb Company, and Genentech, Inc. Lexicon Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in The Woodlands, Texas.
At a Glance
Live SnapshotLexicon Pharmaceuticals, Inc. Cash Conversion Engine
Cash Flow Quality Analysis
FCF Conversion Rate
Excellent cash generation. The company converts earnings to cash at or above 100%, indicating high-quality earnings.
FCF Growth Trend
Strong FCF growth demonstrates improving cash generation and business momentum. Positive signal for sustainability.
Working Capital Impact
Moderate working capital outflow. Typical for growing businesses, but ensure it's supporting revenue growth, not inefficiency.
Cash Flow Quality Insight
Exceptional cash generation: High-quality earnings converting to growing free cash flow. The company demonstrates strong pricing power, efficient operations, and disciplined capital allocation.
Lexicon Pharmaceuticals, Inc. Cash Flow Statement
LXRX • NASDAQ
| Lexicon Pharmaceuticals, Inc. Cash Flow Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | Dec 2008 | Dec 2007 | Dec 2006 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
OPERATING ACTIVITIES | ||||||||||||||||||||
-50.3M | -200.4M | -177.1M | -101.9M | -87.8M | -58.6M | 130.1M | -120.5M | -129.1M | -141.4M | -4.7M | -100.3M | -104.1M | -110.2M | -116.2M | -101.8M | -93.3M | -76.9M | -58.8M | -54.3M | |
621K | 534K | 554K | 427K | 292K | 2.9M | 3.7M | 3.7M | 3.4M | 2.1M | 727K | 1.9M | 2.9M | 4.2M | 4.9M | 5.4M | 6.2M | 10.1M | 10.4M | 11.2M | |
0.0 | 0.0 | 0.0 | 0.0 | 49K | -110K | -6M | 0.0 | -12.7M | 16K | 3.6M | -70K | 0.0 | 0.0 | 116.9M | 4.8M | 2.6M | -26.5M | -20.4M | -7M | |
12.5M | 13.5M | 14.3M | 11.5M | 10.6M | 13.3M | 14.2M | 11.7M | 9.5M | 7.5M | 6.8M | 7.1M | 7.4M | 6.5M | 5.7M | 5.5M | 5.3M | 6.5M | 7.9M | 7M | |
-3.8M | -6.6M | -2.3M | 744K | 54K | -131.6M | 30.1M | 1.3M | 2.7M | -176K | 6.4M | 13.4M | -2.2M | 9.9M | -109.4M | 2.7M | -1.2M | 7.8M | 7.9M | 7M | |
(0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (26K) | (102K) | (0.0) | (0.0) | (0.0) | |
-26.9M | 14.2M | 2.7M | 402K | -10.2M | 31.1M | -58.3M | -44.8M | -59.3M | -43.5M | 171.9M | 2.3M | 5M | -4.8M | 10.2M | 1M | -8.5M | -16.6M | -21.4M | -20.9M | |
-67.9M | -178.8M | -161.9M | -88.9M | -87M | -143M | 113.8M | -148.6M | -185.4M | -175.6M | 184.8M | -75.6M | -91.1M | -94.5M | -87.9M | -82.4M | -89M | -95.6M | -74.3M | -56.9M | |
INVESTING ACTIVITIES | ||||||||||||||||||||
(0.0) | -1M | -470K | -1.3M | -1.2M | -87K | -70K | -95K | -228K | -231K | -910K | -80K | -1.7M | -492K | -1.2M | -1.1M | -369K | -2.2M | -1.9M | -3.6M | |
(0.0) | (0.0) | (0.0) | (69.8M) | -3.3M | (11M) | (155.8M) | (0.0) | (0.0) | (0.0) | (335K) | (0.0) | (0.0) | (0.0) | (0.0) | -5.6M | (0.0) | -20.1M | (0.0) | (0.0) | |
-143.6M | -338.1M | -223.3M | -133.9M | -34.3M | -58.6M | -322.4M | -120M | -267.9M | -425.7M | -326.4M | -222M | -111.5M | -233.3M | -108.1M | -155.9M | -64.2M | -39.8M | -305.7M | -67.7M | |
252.9M | 314.4M | 173.9M | 64.2M | 37.6M | 268M | 166.6M | 289.7M | 318.6M | 444.2M | 210M | 111.4M | 212.6M | 135.9M | 176.6M | 48.6M | 76.3M | 201.4M | 119.7M | 95.7M | |
3.7M | 9.3M | 0.0 | -69.8M | 3.3M | 160.4M | -155.8M | 169.7M | 50.8M | 18.5M | 335K | 2.2M | 130K | 85K | 2.6M | 64K | 107K | 20.1M | 1K | 56K | |
(113M) | -15.4M | -49.9M | -71.1M | (2.1M) | (380.8M) | -155.9M | (169.6M) | (50.5M) | (18.3M) | -117M | -108.4M | (99.5M) | -97.8M | (70M) | -113.8M | (11.9M) | (159.4M) | -188M | (24.5M) | |
FINANCING ACTIVITIES | ||||||||||||||||||||
73K | -1.7M | 138M | 93.3M | 34.4M | 68.9M | -941K | -240K | 6.3M | 3M | -243K | 201.4M | 211K | 37.8M | 160.7M | 181.3M | 55.3M | 1K | 213.1M | 41.5M | |
-48M | 0.0 | 50M | 48.9M | -11.7M | -216.6M | -1.3M | -2M | 143.6M | -2M | -1.9M | 82.4M | -1.6M | -1.4M | -3.6M | -38.5M | 36.5M | -881K | -815K | -751K | |
(0.0) | -1.7M | -824K | -864K | -2.7M | -1M | -941K | -972K | -1.7M | -621K | -357K | -887K | -873K | -285K | -108K | -149K | -88K | (0.0) | (0.0) | (0.0) | |
-572K | -1.2M | 0.0 | 94.2M | 0.0 | 70M | 0.0 | 0.0 | 0.0 | 0.0 | 70K | 0.0 | -26K | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 42.7M | 0.0 | |
-48.5M | 238.3M | 188M | 142.2M | 22.7M | -147.6M | -2.2M | -2.2M | 149.9M | 987K | -2M | 283.8M | -1.4M | 36.4M | 157.1M | 142.9M | 91.8M | -880K | 255M | 40.7M | |
CASH FLOW SUMMARY | ||||||||||||||||||||
-3.3M | 44.2M | -23.9M | -17.7M | -62.2M | 90.2M | -44.3M | 18.7M | 15.1M | -156.4M | 65.7M | 99.8M | 7.1M | -155.9M | 139.1M | -53.3M | 14.7M | 62.9M | -7.3M | 8.3M | |
66.7M | 22.5M | 46.3M | 64.1M | 126.3M | 36.1M | 80.4M | 61.7M | 46.6M | 203M | 137.3M | 37.5M | 30.4M | 186.3M | 47.2M | 100.6M | 85.9M | 22.9M | 30.2M | 22M | |
63.3M | 66.7M | 22.5M | 46.3M | 64.1M | 126.3M | 36.1M | 80.4M | 61.7M | 46.6M | 203M | 137.3M | 37.5M | 30.4M | 186.3M | 47.2M | 100.6M | 85.9M | 22.9M | 30.2M | |
-67.9M | -179.8M | -162.4M | -90.2M | -88.2M | -143.1M | 113.7M | -148.7M | -185.6M | -175.9M | 183.9M | -75.7M | -92.8M | -95M | -89.1M | -83.5M | -89.4M | -97.8M | -76.2M | -60.5M |
SEC Filings
LXRX - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | May 07, 2026 | May 07, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | May 07, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 06, 2026 | May 04, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 30, 2026 | April 30, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | March 16, 2026 | March 16, 2026 | 2026 | |
10-K 10-K 2025 FY FY | March 05, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | March 05, 2026 | March 05, 2026 | 2026 | |
8-K 8-K 2026 N/A | February 02, 2026 | January 29, 2026 | 2026 | |
8-K 8-K 2026 N/A | January 29, 2026 | January 29, 2026 | 2026 | |
8-K 8-K 2025 N/A | November 10, 2025 | November 06, 2025 | 2025 |
Related Guides
Continue your LXRX research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.